WallStSmart

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

NewAmsterdam Pharma Company N.V. Ordinary Shares generates 860% more annual revenue ($7.12M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

NAMS

Avoid

24

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 2/9Altman Z: 3.30

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NAMS2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.3010/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

NAMS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-32.0%2/10

ROE of -32.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : NAMS

The strongest argument for NAMS centers on Debt/Equity, Altman Z-Score.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NAMS

The primary concerns for NAMS are EPS Growth, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

NAMS is growing revenue faster at -80.7% — sustainability is the question.

NAMS generates stronger free cash flow (-39M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NAMS scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

NewAmsterdam Pharma Company N.V. Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address critical unmet medical needs. With an advanced clinical development pipeline and a strategic commitment to reshaping treatment approaches, the company stands poised to significantly influence the healthcare landscape. Guided by a seasoned management team, NewAmsterdam offers a compelling investment opportunity for institutional investors aimed at facilitating transformative healthcare solutions that enhance patient outcomes while ensuring sustainable growth in the biopharmaceutical arena.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?